LIGAND PHARMACEUTICALS INCORPORATED Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
LIGAND PHARMACEUTICALS INCORPORATED (LGND) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $700.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2026-08-07
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $700.00K.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $800.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $102.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $170.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2026-06-30 | $700.00K 10-Q · filed 2026-08-07 |
| 2026-03-31 | $800.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $102.00K 10-K · filed 2026-02-27 |
| 2025-09-30 | $170.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $60.00K 10-Q · filed 2025-08-08 |
| 2025-03-31 | $20.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $31.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | $10.00K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-08 |
| 2023-12-31 | $14.00K 10-K · filed 2025-02-28 |
| 2023-09-30 | $100.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $100.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $100.00K 10-Q · filed 2023-05-08 |
| 2022-12-31 | $162.00K 10-K · filed 2024-02-29 |
| 2020-09-30 | $400.00 10-Q · filed 2020-11-06 |
| 2020-06-30 | $150.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $3.34M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $19.00K 10-Q · filed 2020-11-06 |